findmyKOL
Clinical trialNCT01946568CompletedPhase 1Interventional

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

SponsorDurata Therapeutics Inc., an affiliate of Allergan plcEnrollment36Bacterial Infections.
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Estonia
  • Tallin'S Children Hospital Pediatric Clinic

    Tallinn, Estonia

  • Tartu University Hospital Anesthesiology & Intensive Care

    Tartu, Estonia

United States
  • University Arkansas Medical Center

    Little Rock, Arkansas, United States

  • University of California, San Diego

    San Diego, California, United States

  • Connecicut Children'S Hospital

    Hartford, Connecticut, United States

  • Ann & Robert H. Lurie Children'S Hospital of Chicago

    Chicago, Illinois, United States

  • University of Louisville

    Louisville, Kentucky, United States

  • University of Michigan Medical Center

    Ann Arbor, Michigan, United States

  • Columbia University

    New York, New York, United States

  • Duke Medical Center

    Durham, North Carolina, United States

  • Pediatric Pharmacology

    Toledo, Ohio, United States

  • Texas Children'S Hospital - Clinical Care Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dalbavancin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2013
Primary completion
30 Apr 2015
Completion
30 Apr 2015
Last update posted
23 Jun 2015
Registered enrollment
36
Registry id
NCT01946568
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.